The Court Didn't Officially Do This to the Voting Right Act, But Liberals...
The White House's Picture of Trump and King Charles III Induced a Glorious...
Following SCOTUS Decision, Louisiana Is Wasting No Time Redrawing Its Maps
VP Vance Had the Perfect Analogy for Tim Walz After He Tried to...
Grand Jury Indicts Anti-ICE Protesters Who Assaulted Conservative Journalist
United Pilot's Facebook Header Could Get Him Grounded
Jasmine Crockett Wants Everyone to Know She's Better Than We Are
Vermont Christian School Wins Suit Against State After Being Punished for Trans Athlete...
The 'Devout Catholic' Biden Administration's DOJ Made a Point of Targeting Nuns
Listen to Justice Alito Absolutely Hammer the Lawyer for Haitian Nationals
UCLA Is in Hot Water Over Free Speech, and Here's Why
More Than a Year After the LA Fires, Newsom Is Still 'Clarifying' the...
This Family Lost Their Daughter to an Illegal Alien, and This Is the...
President Trump Is Considering Pulling Troops From Germany Amid Tensions With NATO Countri...
Ayatollah Mojtaba Khamenei Just Issued a New Threat
Tipsheet

FDA Authorizes COVID-19 Booster for Ages 5 to 11

FDA Authorizes COVID-19 Booster for Ages 5 to 11
AP Photo/Ted Jackson

On Tuesday, the U.S. Food and Drug Administration (FDA) authorized a booster dose of the Pfizer-BioNTech COVID-19 vaccine for children ages 5 to 11. 

The FDA published a news release on Tuesday explaining how the single-use booster can be administered to children in this age group at least five months after their primary two-dose vaccine.

Advertisement

“Since authorizing the vaccine for children down to 5 years of age in October 2021, emerging data suggest that vaccine effectiveness against COVID-19 wanes after the second dose of the vaccine in all authorized populations. The FDA has determined that the known and potential benefits of a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age at least five months after completing a primary series outweigh its known and potential risks and that a booster dose can help provide continued protection against COVID-19 in this and older age groups,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, in the release.

Townhall covered in December that the FDA authorized the Pfizer booster for 16 and 17 year olds as the Delta variant spread and the Omicron variant emerged. In early January, the FDA authorized a booster shot for children 12 through 15 years of age.

The release noted that the booster dose for 5 to 11 year olds was assessed in about 400 children five to nine months after they received their primary vaccine dosage. The most common side effects were pain, redness, swelling, fatigue, headache, muscle and joint pains, chills and fever. 

Advertisement

Related:

COVID-19 PFIZER

This age demographic is the youngest to date to receive authorization from the FDA for a COVID-19 booster shot. In February, Townhall reported how Pfizer and BioNTech were testing a third dose of the vaccine, following “disappointing” results from the two-shot regime in children under 5. Shortly after, Pfizer announced it was delaying the application process for Emergency Use Authorization for their vaccine for children ages 6 months through 4 years.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement